Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease
- PMID: 29149768
- DOI: 10.1002/ana.25099
Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease
Abstract
In Parkinson disease (PD), mitochondrial dysfunction associates with nigral dopaminergic neuronal loss. Cholinergic neuronal loss co-occurs, particularly within a brainstem structure, the pedunculopontine nucleus (PPN). We isolated single cholinergic neurons from postmortem PPNs of aged controls and PD patients. Mitochondrial DNA (mtDNA) copy number and mtDNA deletions were increased significantly in PD patients compared to controls. Furthermore, compared to controls the PD patients had significantly more PPN cholinergic neurons containing mtDNA deletion levels exceeding 60%, a level associated with deleterious effects on oxidative phosphorylation. The current results differ from studies reporting mtDNA depletion in nigral dopaminergic neurons of PD patients. Ann Neurol 2017;82:1016-1021.
© 2017 American Neurological Association.
Similar articles
-
Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson disease.Am J Pathol. 2013 Dec;183(6):1826-1840. doi: 10.1016/j.ajpath.2013.09.002. Epub 2013 Oct 4. Am J Pathol. 2013. PMID: 24099985 Free PMC article. Clinical Trial.
-
Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats.Brain Struct Funct. 2016 May;221(4):2319-41. doi: 10.1007/s00429-015-1045-4. Epub 2015 May 20. Brain Struct Funct. 2016. PMID: 25989851
-
Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease.Exp Neurol. 2016 Jan;275 Pt 1:209-19. doi: 10.1016/j.expneurol.2015.11.004. Epub 2015 Nov 10. Exp Neurol. 2016. PMID: 26571193
-
The pedunclopontine nucleus and Parkinson's disease.Neurobiol Dis. 2019 Aug;128:3-8. doi: 10.1016/j.nbd.2018.08.017. Epub 2018 Aug 29. Neurobiol Dis. 2019. PMID: 30171892 Free PMC article. Review.
-
Modulating the cholinergic system-Novel targets for deep brain stimulation in Parkinson's disease.J Neurochem. 2025 Feb;169(2):e16264. doi: 10.1111/jnc.16264. Epub 2024 Nov 18. J Neurochem. 2025. PMID: 39556446 Free PMC article. Review.
Cited by
-
Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson's Disease.Genes (Basel). 2021 Nov 22;12(11):1840. doi: 10.3390/genes12111840. Genes (Basel). 2021. PMID: 34828446 Free PMC article. Review.
-
Resveratrol Inhibits VDAC1-Mediated Mitochondrial Dysfunction to Mitigate Pathological Progression in Parkinson's Disease Model.Mol Neurobiol. 2025 Jun;62(6):6636-6654. doi: 10.1007/s12035-024-04234-0. Epub 2024 May 31. Mol Neurobiol. 2025. PMID: 38819635
-
MtDNA population variation in Myalgic encephalomyelitis/Chronic fatigue syndrome in two populations: a study of mildly deleterious variants.Sci Rep. 2019 Feb 27;9(1):2914. doi: 10.1038/s41598-019-39060-1. Sci Rep. 2019. PMID: 30814539 Free PMC article.
-
Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease.EBioMedicine. 2019 Oct;48:554-567. doi: 10.1016/j.ebiom.2019.09.015. Epub 2019 Oct 17. EBioMedicine. 2019. PMID: 31631040 Free PMC article.
-
Acanthopanax senticosus Protects Structure and Function of Mesencephalic Mitochondria in A Mouse Model of Parkinson's Disease.Chin J Integr Med. 2018 Nov;24(11):835-843. doi: 10.1007/s11655-018-2935-5. Epub 2018 Aug 8. Chin J Integr Med. 2018. PMID: 30090975
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical